What's new

Human medicines European public assessment report (EPAR): Imraldi, adalimumab, Date of authorisation: 24/08/2017, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Imraldi, adalimumab, Date of authorisation: 24/08/2017, Revision: 24, Status: Authorised

Mar 13, 2025 - 15:47
 0
Human medicines European public assessment report (EPAR): Imraldi, adalimumab, Date of authorisation: 24/08/2017, Revision: 24, Status: Authorised
Human medicines European public assessment report (EPAR): Imraldi, adalimumab, Date of authorisation: 24/08/2017, Revision: 24, Status: Authorised
Read More

Tags:

Previous Article

Farms, Food Banks Cut Off Guard By Spending Cuts

Next Article

Human medicines European public assessment report (EPAR): Naveruclif, paclitaxel...

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Olumiant, Baricitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immune system disorders, PIP number: P/0520/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 14, 2025  0

Human medicines European public assessment report (EPAR): Hepcludex, bulevirtide, Date of authorisation: 31/07/2020, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0

Oncology Working Party

Oncology Working Party

Feb 21, 2025  0